Navigation Links
Akela Pharma reports results for third quarter of fiscal 2007
Date:11/9/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: AKL), a drug development company focused on developing therapies for the inhalation and pain markets, today announced its financial results under Canadian generally accepted accounting principles for the three and six month period ended September 30, 2007 and 2006.

Akela's consolidated net loss for the third quarter of 2007 was $8.6 million compared to net income of $12.0 million for the segmented Pharma results for the same 2006 period. The results of operations for the three and nine months ended September 30, 2006 include a gain on disposal of our interest in LAB Research totaling $18.6 million.

"The Third quarter fiscal 2007 was marked by important clinical achievements. We first announced positive results from our GHRH Phase II trial demonstrating a marked stimulation of growth hormone and IGF-1 production followed by positive results for our lead product Fentanyl TAIFUN(R) for the Phase IIb extension arm trial demonstrating efficacy resulting in faster and superior pain relief. Having once again delivered significantly positive clinical milestones we now continue to confidently advance our product development programs." said Dr Halvor Jaeger, Chief Executive Officer of Akela Pharma Inc.

Other Third Quarter Financial Highlights

- Total consolidated revenues for the third quarter of 2007 were

$3.1 million, including $1.1 million in co-development fees and

$1.9 million of contract services. Total consolidated revenues for the

first 9 months of 2007 were $7.9 million, including $1.6 million in

co-development fees and $5.7 million of contract services.

- Consolidated net loss for the third quarter of 2007 was $8.6 million or

($0.73) per share. Consolidated net loss year-to-date is $23.8 million<
'/>"/>

SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
5. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... Fairfax, Va., April 23, 2014 The American Society ... guideline, "The Role of Postoperative Radiation Therapy for ... the use of adjuvant radiation therapy in the ... is published in the May-June 2014 issue of ... clinical practice journal of ASTRO. The full-length guideline ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
(Date:4/23/2014)... detection methods that can rapidly screen a large ... cell inside that population has been seriously lacking," ... In the Royal Society of Chemistry journal ... and his coworkers have developed a novel technique ... ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... elements include platform updates and product road map ... Healthcare developers,can take the next step toward increasing ... 1.3 of Microsoft Health Common User,Interface (CUI), available ... guidance, software toolkit controls and showcase demonstrators,the Microsoft ...
... LONDON, May 13 Chiltern, a leading global ... office in Lisbon,Portugal. Mr. Ricardo Diaz will head ... over 10 years experience in clinical research and,holds ... Clinical trials and,an MBA., The office is ...
... with California Environmental ... Quality Act (CEQA)., LOS ... ahead with the planned expansion of its,Holy Cross Medical Center even ... the approval process was significantly flawed.,The groundbreaking ceremony held today appears ...
... Corporation,(Nasdaq: IOMI ) today said that it will ... today,s announcement that Intercell AG (VSE:,ICLL) and Iomai have ... acquire Iomai for USD 6.60 per share representing a ... 122 million)., The conference call and webcast will ...
... 12 Emphasys Medical Inc.,today announced that one-year ... Zephyr(R) Endobronchial Valve (EBV) will be presented at ... occurring,May 16 to 21 in Toronto, Canada., ... Convention Centre,Room 801A, In the symposium, "Innovations ...
... 12, 2008) - Beta-blocker drugs may help prevent heart ... of death and major stroke, says a major study ... journal, The Lancet. , POISE is the worlds largest ... the effects of a beta-blocker versus placebo given to ...
Cached Medicine News:Health News:Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety 2Health News:Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety 3Health News:Chiltern Announces New Expansion in Portugal 2Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT 2Health News:Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT 3Health News:Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, June 8, 2011 Otonomy, Inc., ... of the ear, today announced positive results for OTO-201, ... in multiple preclinical studies evaluating the treatment of middle ... placement surgery.  Approximately one million tube placement procedures are ...
... NORTH KINGSTOWN, R.I., June 8, 2011 Leading national ... Tufts Health Care Institute,s (THCI) Program on Opioid Risk ... support of THCI,s Program on Opioid Risk Management began ... promoting the safe and effective use of controlled opioid ...
Cached Medicine Technology:Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 2Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 3Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 4Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year 2
... Keep your samples secure in our largest ... storage - enough for 52,700 samples -- ... this ultra-low temperature model utilizes ultra-thin vacuum ... and minimize the footprint. Patented Tollesbury Technology ...
... III, laboratory-grade pure water at a constant ... potable tap water and combine complementary purification ... is easy to operate, reliable, and allows ... a low operating cost., Applications, Glassware ...
... U570 is an upright freezer, built ... models. Comparable in size to Innova ... cascade refrigeration and urethane insulation, for ... 400 2" boxes. Includes five compartments ...
... chest freezer utilizes ultra-thin vacuum insulation ... without increasing the footprint. Patented Tollesbury ... compressor life. Bright LED display shows ... for remote user-supplied monitoring system. Keyed ...
Medicine Products: